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Abstract
Background: The number of residents in long-term care facilities (LTCFs) in need of palliative care is growing in
the Western world. Therefore, it is foreseen that significantly higher percentages of budgets will be spent on
palliative care. However, cost-effectiveness analyses of palliative care interventions in these settings are lacking.
Therefore, the objective of this paper was to assess the cost-effectiveness of the ‘PACE Steps to Success’
intervention. PACE (Palliative Care for Older People) is a 1-year palliative care programme aiming at integrating
general palliative care into day-to-day routines in LTCFs, throughout seven EU countries.
Methods: A cluster RCT was conducted. LTCFs were randomly assigned to intervention or usual care. LTCFs
reported deaths of residents, about whom questionnaires were filled in retrospectively about resource use and
quality of the last month of life. A health care perspective was adopted. Direct medical costs, QALYs based on the
EQ-5D-5L and costs per quality increase measured with the QOD-LTC were outcome measures.
Results: Although outcomes on the EQ-5D-5L remained the same, a significant increase on the QOD-LTC (3.19
points, p value 0.00) and significant cost-savings were achieved in the intervention group (€983.28, p value 0.020).
The cost reduction mainly resulted from decreased hospitalization-related costs (€919.51, p value 0.018).
Conclusions: Costs decreased and QoL was retained due to the PACE Steps to Success intervention. Significant cost
savings and improvement in quality of end of life (care) as measured with the QOD-LTC were achieved. A clinically
relevant difference of almost 3 nights shorter hospitalizations in favour of the intervention group was found. This indicates
that timely palliative care in the LTCF setting can prevent lengthy hospitalizations while retaining QoL. In line with earlier
findings, we conclude that integrating general palliative care into daily routine in LTCFs can be cost-effective.
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Background
Health care costs rise while resources remain limited.
Therefore, providing evidence on health economic evalu-
ations to guide decisions is increasingly important, espe-
cially in palliative care and in long-term care facilities
(LTCFs) [1], because the need for long-term institutional
care for older people is growing as a result of the great
leap in life expectancy achieved in the twentieth century
in Western societies and the related increase in pro-
longed and more complex illness trajectories [2–4]. Con-
sequently, a significant number of frail older people live
in LTCFs and will develop palliative care needs as they
approach the end of life. At the same time, a number of
descriptive studies show that palliative care for this pa-
tient group can be suboptimal: it is not always available,
symptoms appear under-estimated and burdensome
treatments are continued or initiated without having
explored residents’ individual preferences [5–9]. Further-
more, potentially avoidable hospital admissions are com-
mon among LTCF residents [10].
According to the Economist Intelligence Unit, the
growing number of people that might benefit from pal-
liative care will significantly increase the percentage of
budgets spent on palliative care [11]. There are indica-
tions that palliative care interventions are less costly
than usual care or even cost-effective [12]. However,
mostly home, hospital and hospice-based palliative care
programs have been evaluated [12–16]. Therefore, evi-
dence on the cost-effectiveness of palliative care inter-
ventions specifically in LTCFs is needed. In our study,
the EU-funded PACE (Palliative Care for Older People)
Steps to Success intervention, aimed at training LTCF
staff to deliver palliative care to residents, was provided
[17]. Van den Block et al. showed that residents’ comfort
in the last week of life did not change, and that staff had
statistically significantly better knowledge of palliative
care [18].
In this study, new evidence regarding effects on costs
and quality of end of life (care) due to the PACE Steps
to Success intervention is introduced. It aimed to evalu-




This study was part of the EU PACE project [19]. In
PACE, a cluster randomized controlled trial (cRCT) of a
palliative care intervention for residents in LTCFs was
conducted in Belgium (Flanders), Finland, Italy,
Netherlands, Poland, England and Switzerland. In each
country, LTCFs were randomly assigned to either the
intervention condition or to usual care, using stratified
randomization. Pre-specified outcome measures in the
cost-effectiveness analysis were direct medical costs,
quality-adjusted life years (QALYs) based on the
EuroQol-5D-5L (EQ-5D-5L) and costs per quality in-
crease as measured with a specific end of life question-
naire (QOD-LTC). As suggested by the EQUATOR
Network, the CHEERS guideline for economic evaluations
was used [20].
The PACE Steps to Success intervention was imple-
mented over a 12-month period between 2016 and 2017.
Respondents gave informed consent in writing prior to
filling in questionnaires. In Poland and the Netherlands,
this was not required, as questionnaires were filled in
anonymously. The study protocol was approved by
the relevant ethics committees in all participating
countries and was registered at www.isrctn.com –
ISRCTN14741671 (FP7-HEALTH-2013-INNOVATION-
1 603111) on July 30, 2015. This study was supported by
the EU 7th Framework Program, grant agreement
6031111. The funding organization was not involved in
the study design, collection, analysis and interpretation of
the data nor in the decision to approve publication of this
manuscript.
Participants
In each country, researchers randomly selected LTCFs
(clusters) from predefined regions. For eligibility criteria,
see the PACE protocol paper [19]. In each LTCF, resi-
dents who had died over the previous 4-month period
were listed.
Intervention
The ‘PACE Steps to Success’ intervention aims at inte-
grating general palliative care into day-to-day routines in
LTCFs by means of a train-the-trainer approach [19].
The intervention is based on the ‘Route to Success in
Long-term Care Facilities’, developed in the UK [17].
Table 1 shows the six steps of the PACE Steps to Suc-
cess intervention. It was hypothesized that through the
training of facility staff, residents would receive high-
quality palliative care, which in turn would improve the
quality of end of life of these residents. LTCFs assigned
to usual care were allowed to use all (supportive) ser-
vices without restriction.
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Data collection and instruments
The cost-effectiveness of the PACE ‘Steps to Success’
intervention was assessed from a health care perspective,
including direct medical and intervention-related costs.
A cross-sectional study of resident deaths in participat-
ing LTCFs was conducted. LTCFs reported deaths of
residents during the previous 4 months, irrespective of
the place of death. For each case, multiple structured
after-death questionnaires were filled in by a staff mem-
ber most involved (preferably a nurse, otherwise a care
assistant) and a relative at baseline (T0), and post-
intervention at month 13 (T1) and month 17 (T2). See
flowchart in Additional file 1: Fig. S1.
Since the impact of the intervention on both costs and
effects was anticipated to mainly take place in the ter-
minal phase of life, a time horizon of 1 month was
chosen. Questions regarding care services received,
which could be validated by administrative data (filled in
by a staff member) and quality of life (QoL) during the
last month of life (filled in by a staff member and a rela-
tive), were used to determine effects and direct medical
resource use on a per resident basis. Using data from
proxy respondents is a commonly employed approach in
studies of this type and appears to be an acceptable
source of data [21, 22].
Costs
Quantities of resources used in the last month of life
(hospital admissions, visits of health care professionals,
received intensive treatments like CPR or surgery (yes or
no), see Additional file 2: Table S1) were multiplied by
standard unit costs in euros. These unit costs were based
on reference prices from 2017, the year the intervention
was provided, calculated by the Dutch National Health
Care Institute (ZN) and average per unit sales prices
established by the Dutch Health Care Authority (NZA).
If prices were only available for other years, they were
adjusted using the consumer price index published by
Statistics Netherlands [23]. If they were not available,
health insurer contract rates were used. By using stand-
ard unit costs, the price parameter was kept constant
over countries, so that results of the cost-effectiveness
analysis could be explained by variances in volumes re-
source use only. See Additional file 2: Table S1 for the
clustered care units that were used to measure resource
use, including tariffs.
Mean costs associated with the intervention (hours
dedicated to the intervention of coordinators and
trainers, materials, accommodation) were identified and
calculated back to resident level by multiplying the
LTCFs’ number of beds by the occupancy rate. See Add-
itional file 2: Fig. S2. In this calculation, the turnover
rate of residents was considered. Since little is known
about the sustainability of complex interventions in
long-term care [24], a comprehensive discussion within
the PACE consortium was held. As a conclusion, a de-
preciation period of 3 years was chosen as base-case.
Subsequently, sensitivity analyses to determine the im-
pact of the depreciation period were conducted in which
it was assumed the effect of the intervention would wear
off a shorter period of time.
Effects
The 5-level EQ-5D version (EQ-5D-5L) and the Quality
of Dying in Long-Term Care (QOD-LTC) were used to
measure intervention effects. The EQ-5D-5L measures
five health-related QoL domains: mobility, self-care,
usual activities, pain/discomfort and anxiety/depression.
Preferences for the EQ-5D-5L were based on value sets
from England [25, 26] and were elicited by means of
both time trade-off and discrete choice experiments
[26]. The use of the EQ-5D is recommended by inter-
national guidelines on economic evaluation [27, 28],
making it the most often used outcome measure in eco-
nomic evaluations in health care, increasing the compar-
ability of results across literature. As suggested in earlier
Table 1 The six steps of the ‘PACE Steps to Success intervention’
Step Content of the step
Discussions as the end-of-life
approaches
Advance care planning discussions with residents and/or families are conducted to elicit wishes and
preferences around end-of-life care.
Assessment, care planning and review A ‘Mapping Changes in Condition chart’ is used monthly by nurses and care assistants to plot changes
(deterioration and improvement) in a resident’s physical condition.
Coordination of care Using a Palliative Care Register, residents who are identified as expected to live less than 6 months are
discussed in detail during monthly multidisciplinary review meetings. A summary sheet is sent to
physicians who were not able to attend the meeting.
Delivery of high-quality care Staff learns about symptom control and complex communication skills, with a focus on pain and
depression.
Care in the last days of life The Last Days of Life checklist prompts and guides the care in the last days of life, with a focus on
recognizing dying, communication with family, regular assessment of symptoms, anticipatory medication
prescription, hydration, and psychosocial and spiritual support.
Care after death Reflective meetings following a death are held to support staff and encourage experiential learning.
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work [29], in this study, a specific QoL instrument for
palliative care was used in addition to the EQ-5D. The
QOD-LTC covers both quality of care (64%) and quality
of dying (36%) items, measures psychosocial quality of
end of life (care) and comprises three subscales: person-
hood, closure and preparatory tasks [30].
Statistical analyses
Differences in both costs and effects were analysed by
means of regression analyses, with LTCF as the cluster.
A mixed model approach was used, as this is able to
capture the design complexity and correlation structures.
Cost-effectiveness was integrated in one outcome meas-
ure, the net monetary benefit (NMB), and used as a
dependent variable in the mixed model [31]. The NMB
is a summary statistic representing the value of the inter-
vention in monetary terms when a willingness-to-pay for
a unit of effect, such as the QALY, is assumed. If the net
value of the benefits outweighs the costs, the investment
is said to increase health. If a reduction in costs at equal
effects is realized, cost-minimization is pursued.
Covariates considered were age, gender, disease sever-
ity (measured with the Bedford Alzheimer Nursing Se-
verity Scale – BANS-S, range 7–28), baseline
measurement and the treatment dummy (intervention
vs. control). Baseline measurement was taken into ac-
count to control for differences on baseline in case mix
(regarding characteristics of residents) between LTCFs,
both between and within countries. Since costs normally
are right skewed—there are no negative costs, and some
patients incur high costs (outliers)—a non-parametric
bootstrap, in which we randomly sampled with replace-
ment, was performed. This approach avoids the need to
make assumptions about the shape of the distribution
but instead uses the observed distributions of the stud-
ies’ cost data [32]. Analyses were on an intention-to-
treat and complete case analysis was pursued.
Results
Deceased residents from 73 LTCFs1 from seven coun-
tries were identified. Concerning deceased residents, we
collected 551 of 610 questionnaires from staff at baseline
(90.3%) and 984 of 1178 post-intervention (83.5%) in 37
intervention and 36 control homes. Two hundred fifty-
nine of 467 questionnaires from relatives were collected
at baseline (55.5%) and 498 of 939 post-intervention
(53.0%). We report on findings from both groups but
focus on findings from staff questionnaires because of
the considerably higher response rate. In addition, within
the European context, nurses’ perceptions seem to align
more closely with those of patients than perceptions of
relatives do [33, 34].
The mean age of the deceased residents was 85.7 years,
with a BANS-S disease severity score of 19.1 (range 7–
28), and 65% was female. Resident characteristics in
intervention and control LTCFs at baseline (T0) and
post-intervention (T1 + T2) were broadly comparable.
See Table 2.
Costs
Between baseline and post-intervention, costs in the
last month of life increased by €600.75 for residents
dying in control LTCFs and decreased by €257.52 for
residents dying in LTCFs receiving the PACE Steps to
Success intervention. See Table 3. After bootstrapping
and controlling for age, gender, residents’ disease se-
verity, country, baseline measurement and group, a
significantly lower cost of €983.23 for residents dying
in intervention LTCFs was found. See Table 4. This
decrease in cost was mainly due to significantly lower
costs related to hospital admission (− €919.51, see
Additional file 3: Table S2). This decrease can be ex-
plained by a combination of shorter length of hospi-
talizations and the type of wards residents were
admitted to, although both elements did not decrease
significantly on their own. Of those residents admit-
ted, between pre- and post-test admission decreased
with 2.2 nights in the intervention group and in-
creased with 0.7 nights in the control group (a differ-
ence of 2.9 nights in favour of the intervention
group). Moreover, mainly costs related to hospitaliza-
tions on the geriatric, general and ICU ward de-
creased (80.6% of total cost decrease). The above
figures are based on a 3-year depreciation period,
resulting in intervention-related costs of €124.08 per
resident in the intervention arm. When bringing back
the depreciation period to 1 year, the intervention still
brought about significantly lower costs (− €934,84, 95% CI
− €1713,78 to − €273,02, p value 0.023).
Effects
After bootstrapping and controlling for age, gender, resi-
dents’ disease severity, country, baseline measurement
and group, no significant differences in quality of end of
life as measured with the EQ-5D-5L were found between
intervention and control LTCFs between baseline and
post-intervention. The QOD-LTC significantly improved
for residents dying in LTCFs receiving the intervention
(3.19, 95% CI 1.72–4.65, p value 0.00). See Tables 3 and
4. The fact both measures show a low correlation (Pear-
son’s coefficient, 0.14) confirms the relevance of not only
measuring HR-QoL through the EQ-5D-5L when doing
CEAs in palliative care, as suggested in earlier work [29].
1Of the 78 recruited LTCFs, three dropped out; one had no deaths to
report on, and one returned no questionnaires post-intervention.
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Cost-effectiveness
The PACE Steps to Success intervention dominated the
common practice alternative (control). It appeared both
cheaper (− €983,28, p 0.02) and more effective on the
QOD-LTC or not significantly different on the EQ-5D-
5L. See Table 4. The NMB over the total relevant
willingness-to-pay range for a QALY gained, from
€20.000 to €80.000, in this study is therefore always big-
ger than zero, meaning added value. Because no signifi-
cant differences were found on the EQ-5D-5L, the NMB
was not considered in a mixed model as the decision
rule changed to cost-minimization.
Discussion
Costs decreased and QoL was retained due to the PACE
Steps to Success intervention. The 1-year palliative care
programme realized significant cost savings and im-
proved quality of end of life (care) in the last month of
life (QOD-LTC), meaning it strengthened sense of per-
sonhood, closure and preparatory tasks. Outcomes on
the EQ-5D-5L were unchanged. Cost savings mainly
resulted from decreased hospitalization-related costs. A
clinically relevant difference of almost 3 nights shorter
(from 9 to 6 nights; a decrease of 30%) hospitalizations
in favour of the intervention group was found, indicating
residents are returning to their LTCF earlier. Mainly
costs related to hospitalizations on the geriatric, general
and ICU ward decreased (80.6% of total cost decrease).
Although the length of hospitalization and the cost de-
crease on the mentioned wards did not decrease signifi-
cantly, the combination of both components of the
composite outcome pointing in the same direction
resulted in a significant cost decrease.
The decrease on these specific wards plausibly is not
by chance. Patients entering the hospital normally are
screened on the general ward, and on the geriatric ward,
the desirability of care is discussed. In our study, this
work was already done in the LTCF through the PACE
intervention. Regarding the decrease on the ICU, the
discussions with residents and families to elicit wishes
and preferences around EoL as part of the PACE inter-
vention in the LTCF presumably made residents and
staff not prefer intensive hospital care anymore, mostly
as the condition of the resident is too frail to profit from
such intensive care and might even be harmful. A recent
review showed that comparable interventions are found
to decrease life-sustaining treatment and prevent
hospitalization [35]. A JAMDA review found that in the
nursing home population, ACP decreased hospitalization
rates up to a quarter [36]. In line with these findings, we
therefore conclude that investing in palliative care train-
ing for LTCF staff can increase quality of care and the
last phase of life and reduce direct medical costs.
Concerning the effects on the cost side, our finding
that the PACE Steps to Success intervention influences
costs related to hospitalizations in the last month of life
is in line with earlier research showing hospital admis-
sion in the last phase of life generally speaking are found
to be undesirable, as patients mostly prefer less intensive
treatment and desire comfort care during the end of life
[37, 38]. One study even showed that higher health care
costs in the last phase of life were associated with worse
quality of death [39]. Also from a health care perspec-
tive, this finding is highly relevant as potentially avoid-
able hospital admissions are common among LTCF
residents [10], and costs involved with hospital
Table 2 Resident characteristics control and intervention LTCFs on baseline and post-intervention
Baseline (T0) Post-intervention (T1 + T2)
Control (n = 272) Intervention (n = 279) Control (n = 558) Intervention (n = 425)
Mean age 85.22 85.68 85.58 85.91
% female 70.6 60.6 64.7 64.0
BANS-S 19.93 19.03 18.95 18.75
% dementia 71.8 70.3 71.8 66.8
Table 3 Mean costs resource use and quality of end of life effects last month of life for control and intervention LTCFs on baseline
and post intervention (unadjusted)
Baseline (T0) Post-intervention (T1 + T2)
Control (n = 272) Intervention (n = 279) Control (n = 558) Intervention (n = 425)
Mean costs resource use €1,361.89 €1,667.87 €1,962.64 €1,410.35
EQ-5D-5L (range 0–1) 0.159a 0.210a 0.196a 0.186a
0.155b 0.130b 0.160b 0.160b
QOD-LTC (range 11–55) 38.24 37.84 38.34 40.96
aStaff member (nurse or care assistant) most involved
bRelative
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admissions typically represent a considerable percentage
of total spending in the last months of life [40]. Never-
theless, there seems to be room for improvement as the
number of hospitalizations and intensive treatments did
not decrease. Further research is needed focusing on
identifying those residents most at risk for hospitaliza-
tions and decreasing those that are avoidable.
Moreover, with regard to the impact on the effect side,
the realized improvement on the QOD-LTC, measuring
both items related to quality of care and quality of dying
[41], evidently is highly desirable as palliative care for
the subject patient group can be suboptimal, and oppor-
tunities for improvement in terms of QoL in the last
phase of life in LTCFs are notable [5–9]. As communica-
tion, assessment and care planning are core components
of the PACE Steps to Success intervention, the signifi-
cant improvement on the QOD-LTC is plausible. Since
no significant differences were found on the EQ-5D-5L,
utilities are not available for the QOD-LTC, and survival
effects were not to be expected [42], QALYs were not
calculated in this study. If survival would have been in-
fluenced though, this was missed.
Strengths and weaknesses
This pioneering large-scale study is the first to inter-
nationally consider the cost-effectiveness of a palliative
care intervention in LTCFs. As suggested in earlier work
[29], a specific QoL instrument for palliative care in the
form of the QOD-LTC was used in addition to the EQ-
5D-5L as the latter is mainly concerned with health and
the recovery of health and contains domains often seen
as less relevant in the context of palliative care, in which
values such as patient dignity, spiritual and psychosocial
wellbeing and bereavement support are central. Another
strength is the homogeneous study group: only data
concerning the last weeks of life of residents were used.
In earlier research, it was argued that using back-
ward counting to chart health care utilization might
not give full insight in costs involved [43], as patients
receiving palliative care might live longer, resulting in
higher costs for additional care which might eclipse
the savings accrued through lower intensity of care at
the end of life [44–46]. However, these findings could
not be replicated in recent systematic reviews [42,
47]. Moreover, the fact our study was assessed from a
health care perspective, excluding informal care costs
such as out-of-pocket payments of relatives and costs
associated with loss in productivity (such as absentee-
ism), plausibly has not caused considerable bias as
presumably fairly limited informal care costs (e.g. out-
of-pocket expenses and productivity losses) are in-
volved with residents living in LTCFs. As the focus
was on volume changes, not on price effects, the fixed
tariffs for care were used. Nevertheless, when using a
general tariff for nights spent in the hospital, a sig-
nificant cost decrease was still found. However, na-
tional profits evidently differed per country, as for
example labour cost is lower in Poland than the
Netherlands. Combining of post-intervention data (at
T1 and T2) because of a lower-than-expected re-
sponse rate did not influence our findings: significant
cost-savings were found on both time points.
The fact treatments received had to be dichoto-
mized is a limitation though, as it was not captured
if residents had multiple same treatments. Moreover,
value sets from England were used to achieve utility
scores for the EQ-5D-5L—ranging from 0 (death) to
1 (perfect health)—since value sets were not avail-
able for all participating countries [25, 26]. It would
be valuable for future studies to be able to use
population-specific valuation sets better reflecting
cultural differences and so increase validity of the
measurement [48]. Also, the UK National Institute
for health and Care Excellence (NICE) does not rec-
ommend using the EQ-5D-5L value set [49], because
of concerns regarding its quality and reliability [50,
51]. Furthermore, using a 3-month period has been
tested in previous research and has been shown to
limit recall bias [7, 52–54]. In the PACE study, this
period was lengthened to 4 months when LTCFs ex-
ceptionally did not meet minimal numbers of inclu-
sion. Because of this, some memory bias might have
occurred. Additionally, data were collected retro-
spectively over the last month of life in the PACE
project [2]. Therefore, sensitivity analysis considering
longer time horizons was not possible. Lastly, re-
spondents were not blinded post-intervention. This
might have influenced their responses, as staff may
have wanted to report better quality after the inter-
vention. However, the fact the study did not find
Table 4 Adjusted mean differences in costs resource use and quality of end of life effects last month of life, incl. 95% CIs and P
values
Baseline (T0) Post-intervention (T1 + T2)
Mean difference 95% CI P value Mean difference 95% CI P value
Mean costs resource use €382.56 − €240.29 to €1136.67 0.15 − €983.28 − €1,762.22 to − €321.46 0.02
EQ-5D-5L (range 0–1) 0.035 − 0.186–0.884 0.20 − 0.038 0.087–0.011 0.13
QOD-LTC (range 11–55) − 1.09 − 3.15–0.96 0.29 3.19 1.72–4.65 0.00
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improvements on staff-reported comfort in the last
week of life in the intervention group [18] suggests
that this will have been limited.
Generalizability and future research
Although a pattern of palliative care interventions
being less costly than their comparators was also re-
cently found in a review study [12], relatively little is
known on the cost-effectiveness of palliative care, es-
pecially within LTCFs. Only O’Sullivan et al. on a
national level looked at this specific setting and in
line with our findings saw a significant decrease in
hospitalization related costs [55]. Future research
could look into possibilities of using better fitting
QoL measurement tools—for example building on
the capabilities approach [56]—for patient groups for
which health-related QoL outcomes are too narrow
[29, 57], and calculating utilities for these tools.
Moreover, we suggest looking into possibilities of
investing savings due to interventions like ‘PACE
Steps to Success’ in quality palliative care in LTCFs.
Conclusions
Costs decreased and QoL was retained due to the PACE
Steps to Success intervention. This study showed that
the PACE Steps to Success intervention is cost-effective.
Direct medical costs significantly decreased, mainly due
to significantly lower hospitalization related costs (−
€983.28, 95% CI − €1762.22 to − €321.46, p value 0.02)
and quality of end of life (care) in the last month of life
(QOD-LTC) significantly improved (3.19, 95% CI 1.72–
4.65, p value 0.00). There is room for improvement
though. Further zooming in on which hospitalizations
are justifiable and which are not is recommended. Fur-
thermore, rolling out the intervention by continuous
training might also positively impact the number of hos-
pitalizations and intensive treatments in the last month
of life.
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